{
  "docId": "019de514-4d4c-7369-a2bf-f736423e3911",
  "docSlug": "b1cdb8c0597ad8aabf7d9d24c5430a53",
  "documentTitle": "Imara | Mergers and Acquisitions Presentation Deck | 45 slides",
  "authorId": "imara",
  "authorName": "Enliven Therapeutics / Imara",
  "documentKindSlug": "press-release",
  "documentKindLabel": "Press release",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 45,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide outlines the strategic positioning of a drug candidate (ELVN-001) by contrasting its desired profile against current standards of care.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de514-4d4c-7369-a2bf-f736423e3911/25",
  "deckHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911",
  "deckJsonHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911.json",
  "deckAnchorHref": "/decks/019de514-4d4c-7369-a2bf-f736423e3911#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.64,
        "y": 0.215
      },
      "kind": "list",
      "text": "Dose Escalation in 3L+ and Expansion: Progressed/Intolerant CP-CML, Explore early LoT & combinations, Seek to demonstrate improved efficacy and tolerability",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "15d2598f-6b3f-4f63-bfb9-1b41ddef4617",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.64,
        "y": 0.72
      },
      "kind": "list",
      "text": "Early Line H2H vs Physician's Choice: Superiority based on 12m MMR in CP-CML; Fewer dose reductions/discontinuations vs. approved agents",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4447249d-abdf-4634-bb19-42384920781e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.08,
        "y": 0.54
      },
      "kind": "list",
      "text": "Activity against native BCR-ABL and T315I mutation; High selectivity; Efficacy: MMR greater than approved TKIs; Tolerability: fewer dose reductions; Safety: No black box warnings; No restrictions with concomitant medications",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88559985-290e-4839-b42d-46cafe4c1389",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.64,
        "y": 0.48
      },
      "kind": "list",
      "text": "4L+ and T315I mutation: Single-arm study; precedent for approval in last line based on CCyR/MMR by 12m; T315I mutation in ponatinib or asciminib progressed/intolerant/ineligible",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e22b0612-35e4-4edb-a3b3-0f22b1034039",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.4,
        "x": 0.08,
        "y": 0.315
      },
      "kind": "list",
      "text": "Drive Deeper Responses, Improve Tolerability, Enhance Safety & Convenience",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e96d7dee-dd0d-4c67-ab0f-e0011317e11a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.08,
        "y": 0.215
      },
      "kind": "paragraph",
      "text": "Our Opportunity",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27aff22e-2817-4838-a506-90b279b75da7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.2,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "paragraph",
      "text": "Target Product Profile",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8d3edc12-5176-45d8-8687-a32d4854710d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.93
      },
      "kind": "source-note",
      "text": "CCyR = Complete cytogenetic response. CP-CML = Chronic phase CML. H2H = Head-to-head. LoT = Line of therapy. MMR = Major molecular response. MR4.5 = Deep molecular response. TKI = Tyrosine kinase inhibitors",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f295fe98-b670-4fa4-810a-9738c6224c1e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.06
      },
      "kind": "title",
      "text": "ELVN-001 Clinical Focus and Target Product Profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5c796489-aea0-487c-afae-95b47a716cf4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "b267e215-0cde-4f60-b20f-677ad90c7d6a",
      "evidence": "list/bullet with multiple items",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 10,
      "beatId": "d6182004-7274-41e9-b235-3a0a93f6cc05",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The document presents ELVN-001 and ELVN-002 as potential solutions to the problem, with a focus on their clinical focus and target product profiles.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "cb84aefe-a7ad-46b2-afcc-84f44e849500",
      "evidence": "The document discusses the limitations and toxicity of current treatments for CML, highlighting the need for better options.",
      "position": 0,
      "objective": "What are the consequences of not having better treatment options for CML?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}